Answer ... The Amendment Communiqué (see question 1.1) has amended the turnover thresholds that a given merger or acquisition must exceed in order to be subject to notification for the purposes of the Turkish merger control regime. Following the enactment of the amendments, the thresholds under Article 7 are as follows:
- Article 7(a): The total turnover in Turkey of the parties to a concentration exceeds TL 750 million and the Turkish turnover of at least two parties each exceeds TL 250 million.
-
Article 7(b): Either:
-
- the Turkish turnover of the transferred assets or businesses being acquired (as well as joint ventures) exceeds TL 250 million and the worldwide turnover of at least one of the other parties to the transaction exceeds TL 3 billion (Article 7(b)(i)); or
- the Turkish turnover of any of the parties being merged exceeds TL 250 million and the worldwide turnover of at least one of the other parties to the transaction exceeds TL 3 billion (Article 7(b)(ii)).
- The tests under Article 7(b) thus include two separate tests: Article 7(b)(i) is applicable only to acquisitions (as well as joint ventures), while Article 7(b)(ii) is applicable only to mergers.
Furthermore, the Amendment Communiqué has introduced a threshold exemption for undertakings active in the following fields:
- digital platforms;
- software or gaming software;
- financial technologies;
- biotechnology;
- pharmacology;
- agricultural chemicals; and
- health technologies.
Pursuant to the Amendment Communiqué, special thresholds will apply to acquired undertakings active in, or assets relating to these fields if they:
- operate in the Turkish geographical market;
- conduct research and development activities in the Turkish geographical market; or
- provide services to Turkish users.
Therefore, the Amendment Communiqué does not require a Turkish nexus for activities to qualify for the threshold exemption. In other words, it will suffice if the target is active in one of the relevant fields anywhere in the world in order for the threshold exemption to apply. Accordingly, for the threshold exemption to apply, the target need not:
- generate revenue from customers located in Turkey;
- conduct research and development activities in Turkey; or
- provide services to Turkish users.
If the target is active in one of the relevant markets/sectors, the following thresholds will apply:
- The aggregate Turkish turnover of the transaction parties exceeds TL 750 million; or
- The worldwide turnover of at least one of the other parties to the transaction exceeds TL 3 billion.
Accordingly, where an undertaking that meets these criteria is being acquired, the transaction will be notifiable if either:
- the aggregate Turkish turnover of the target and the acquirer exceeds TL 750 million; or
- the worldwide turnover of the acquirer exceeds TL 3 billion.
Clarifications on the meaning and the scope of the relevant markets/sectors are provided in question 1.2.
Where the transaction does not meet the above thresholds, the transaction will not be deemed notifiable. Furthermore, Communiqué 2010/4 does not require the existence of an ‘affected market’ in assessing whether a transaction triggers a notification requirement.
In terms of the above threshold exemption for certain undertakings, reasoned decisions of the Competition Board have begun to be published, slowly creating precedent on the issue. Of the approximately 10 decisions in which the relevant exemption was applied, examples include:
- IFGL/Cinven (Decision 22-23/372-157 of 18 May 2022), which concerned an undertaking active in the digital platform markets;
- Airties/Providence (Decision 22-25/403-167 of 2 June 2022), which concerned a programming undertaking;
- Affidea/GBL (Decision 22-27/431-176 of 16 June 2022), which concerned a biotechnology undertaking;
- Clayton/TPG/Covetrus (Decision 22-32/512-209 of 7 July 2022), which concerned a pharmacology undertaking;
- Astorg/Corden (Decision 22-25/398-164 of 2 June 2022), which concerned a pharmacology undertaking;
- Biocon Viatris (Decision 22-23/380-159 of 18 May 2022), which concerned a pharmacology/molecular medicine undertaking;
- Citrix/Tibco (Decision 22-21/344-149 of 12 May 2022), which concerned a software undertaking; and
- Impala Bidco/HG Capital/EQT Fund/TA (Decision 22-21/354-152 of 12 May 2022), which concerned technology undertakings.
Finally, Communiqué 2017/2 Amending Communiqué 2010/4 on Mergers and Acquisitions Requiring the Approval of the Board removed the provision of Article 7(2) of Communiqué 2010/4 stating that “The thresholds … are re-determined by the Board biannually”. As a result, the Competition Board is no longer required to review the turnover thresholds for concentrations every two years.